In order to assess the in vivo use of sCD5 as a decoy receptor in cancer therapy, a transgenic mouse line that constitutively expresses the soluble portion of human CD5 (shCD5) under control of the non-tissue specific SV40 promoter and immunoglobulin μ heavy chain enhancer (Eμ) was developed [69]. Here, CD5 is linked to cancer.